Loading…
Accent Microcell (ACCENTMIC)₹602.70−2.79%Pharmaceuticals
In the Mar 2026 quarter (standalone), Accent Microcell reported sales of ₹210 Cr, up 51.1% from Mar 2025, and net profit of ₹26.04 Cr, up 52.9% year on year. For the year to Mar 2026, sales were ₹349 Cr and net profit ₹44.07 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 107 | 139 | 126 | 139 | 139 | 210 |
| Expenses | 86.97 | 119 | 107 | 115 | 115 | 177 |
| Operating Profit | 20.03 | 20.03 | 19.02 | 23.01 | 24.01 | 33.02 |
| OPM % | 18.0% | 14.0% | 15.1% | 17.0% | 17.0% | 16.0% |
| Other Income | 0.99 | 1.99 | 2.99 | 2.99 | 2.99 | 3.99 |
| Interest | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.99 |
| Profit before tax | 16.93 | 18.93 | 19.92 | 23.89 | 23.90 | 33.89 |
| Tax % | 17.9% | 16.9% | 15.9% | 31.9% | 24.9% | 24.9% |
| Exceptional items | −0.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 14.03 | 16.04 | 16.04 | 17.03 | 18.05 | 26.04 |
| EPS (Rs) | 8.02 | 6.71 | 6.87 | 6.93 | 7.54 | 10.76 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 114 | 131 | 133 | 166 | 197 | 246 | 265 | 349 |
| Expenses | 108 | 122 | 122 | 153 | 178 | 206 | 223 | 292 |
| Operating Profit | 6.01 | 9.01 | 11.01 | 13.01 | 19.02 | 39.05 | 42.02 | 57.04 |
| OPM % | 4.9% | 7.0% | 8.0% | 8.0% | 10.1% | 16.0% | 16.0% | 16.0% |
| Other Income | 5.99 | 3.99 | 1.99 | 1.99 | 1.99 | 2.99 | 5.99 | 6.98 |
| Interest | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 1.01 | 0.00 | 1.01 |
| Depreciation | 2.99 | 2.99 | 3.98 | 3.98 | 3.99 | 3.99 | 3.99 | 4.98 |
| Profit before tax | 4.98 | 5.98 | 5.98 | 7.97 | 14.93 | 36.87 | 43.80 | 57.81 |
| Tax % | 23.9% | 30.9% | 19.9% | 21.9% | 16.9% | 16.9% | 23.9% | 24.9% |
| Exceptional items | 0.00 | 0.00 | −0.23 | 0.00 | 0.00 | −0.84 | 0.00 | 0.00 |
| Net Profit | 4.01 | 4.01 | 5.01 | 6.02 | 12.03 | 30.08 | 33.07 | 44.07 |
| EPS (Rs) | 7.40 | 8.54 | 9.82 | 4.02 | 8.27 | 12.58 | 13.80 | 18.29 |
| Dividend payout % | 0.0% | 0.0% | 9.1% | 18.1% | 8.0% | 7.0% | 6.0% | 5.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 4.00 | 13.01 | 13.02 | 21.05 | 21.05 | 24.06 |
| Reserves | 17.00 | 20.99 | 21.99 | 18.98 | 37.01 | 143 | 174 | 252 |
| Borrowings | 32.06 | 30.03 | 31.04 | 24.03 | 23.04 | 13.03 | 2.00 | 1.00 |
| Other Liabilities | 20.09 | 22.11 | 23.11 | 38.19 | 37.18 | 28.13 | 32.15 | 45.21 |
| Total Liabilities | 73.15 | 77.13 | 81.14 | 95.21 | 111 | 205 | 229 | 323 |
| Fixed Assets | 30.05 | 29.04 | 30.07 | 30.08 | 31.07 | 29.05 | 48.07 | 53.08 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 13.02 | 102 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 43.10 | 48.09 | 50.07 | 64.13 | 79.18 | 174 | 168 | 167 |
| Inventories | 13.99 | 17.99 | 31.98 | 39.99 | 42.02 | 32.99 | 34.03 | 31.99 |
| Trade receivables | 22.06 | 22.06 | 13.03 | 17.04 | 30.06 | 54.14 | 65.15 | 91.17 |
| Cash & equivalents | 2.99 | 3.99 | 0.99 | 2.99 | 1.99 | 71.95 | 50.96 | 19.96 |
| Total Assets | 73.15 | 77.13 | 81.14 | 95.21 | 111 | 205 | 229 | 323 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 5.98 | 4.99 | 4.99 | 14.97 | 7.98 | 10.98 | 24.92 | 18.94 |
| Cash from investing activity | −3.99 | −1.99 | −5.99 | −3.99 | −3.99 | −81.93 | −8.98 | −48.94 |
| Cash from financing activity | −0.99 | −1.99 | −1.99 | −9.97 | −3.98 | 71.78 | −13.94 | 35.89 |
| Net cash flow | 1.01 | 1.01 | −3.01 | 1.01 | −1.01 | 1.01 | 2.01 | 6.01 |
| Capex | 4.01 | 2.01 | 5.01 | 4.01 | 4.01 | 13.04 | 37.07 | 88.24 |
| Free cash flow | 1.99 | 2.99 | 0.00 | 10.99 | 2.99 | −1.99 | −11.98 | −67.90 |
| CFO / OP % | 120.0% | 72.0% | 57.0% | 127.0% | 53.0% | 44.0% | 85.0% | 56.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 71 | 61 | 36 | 39 | 57 | 81 | 90 | 96 |
| Inventory days | 67 | 78 | 128 | 128 | 128 | 83 | 76 | 55 |
| Days payable | 90 | 81 | 75 | 98 | 107 | 49 | 43 | 34 |
| Cash conversion cycle | 47 | 57 | 87 | 67 | 78 | 113 | 123 | 116 |
| Working capital days | 20 | 31 | 38 | 17 | 42 | 80 | 102 | 96 |
| ROCE % | — | 18.1% | 17.0% | 19.0% | 27.1% | 31.1% | 24.1% | 25.0% |
For the Mar 2026 quarter, Accent Microcell reported sales of ₹210 Cr, up 51.1% year on year and net profit of ₹26.04 Cr, up 52.9% year on year. The operating margin was 16.0%.
Accent Microcell's sales for the year to Mar 2026 were ₹349 Cr.
Net profit for the year to Mar 2026 was ₹44.07 Cr. Earnings per share over the same trailing period were ₹18.29.
Accent Microcell reported borrowings of ₹1 Cr at Mar 2026, against cash and equivalents of ₹19.96 Cr.
Cash from operations was ₹18.94 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹67.90 Cr.